Technical Analysis for TARS - Tarsus Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
C 30.61 -3.07% -0.97
TARS closed down 3.07 percent on Monday, March 18, 2024, on 56 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
2 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Down

Date Alert Name Type % Chg
Multiple of Ten Bullish Other 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
Multiple of Ten Bullish Other -3.07%
Wide Bands Range Expansion -3.07%
Oversold Stochastic Weakness -3.07%
50 DMA Support Bullish 4.01%
Multiple of Ten Bearish Other 4.01%
Wide Bands Range Expansion 4.01%
Oversold Stochastic Weakness 4.01%

   Recent Intraday Alerts

Alert Time
Down 5% about 12 hours ago
Fell Below Previous Day's Low about 12 hours ago
60 Minute Opening Range Breakdown about 13 hours ago
Down 3% about 16 hours ago
Down 2 % about 16 hours ago

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase IIb/III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. Tarsus Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Irvine, California.
Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Organ Systems Ophthalmic Malaria Rosacea Blepharitis Meibomian Gland

Is TARS a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 40.4
52 Week Low 11.33
Average Volume 746,052
200-Day Moving Average 20.36
50-Day Moving Average 29.25
20-Day Moving Average 33.56
10-Day Moving Average 32.51
Average True Range 2.19
RSI (14) 46.24
ADX 32.78
+DI 20.65
-DI 26.48
Chandelier Exit (Long, 3 ATRs) 33.82
Chandelier Exit (Short, 3 ATRs) 35.00
Upper Bollinger Bands 39.79
Lower Bollinger Band 27.33
Percent B (%b) 0.26
BandWidth 37.11
MACD Line 0.35
MACD Signal Line 1.27
MACD Histogram -0.9221
Fundamentals Value
Market Cap 1.01 Billion
Num Shares 33.1 Million
EPS -3.84
Price-to-Earnings (P/E) Ratio -7.97
Price-to-Sales 72.00
Price-to-Book 4.83
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 32.88
Resistance 3 (R3) 32.87 32.10 32.50
Resistance 2 (R2) 32.10 31.53 32.11 32.37
Resistance 1 (R1) 31.36 31.17 30.98 31.37 32.25
Pivot Point 30.59 30.59 30.40 30.60 30.59
Support 1 (S1) 29.85 30.02 29.47 29.86 28.97
Support 2 (S2) 29.08 29.66 29.09 28.85
Support 3 (S3) 28.34 29.08 28.72
Support 4 (S4) 28.35